mecaib
Bluelighter
Hello,
I've got a question for you guys.
It has become well-known that 5-HT2A receptor agonists prevent NMDA antagonist neurotoxicity in rats:
http://www.nature.com/npp/journal/v18/n1/abs/1395108a.html
I plan to take a dissociative soon. I take 30mgs mirtazapine each night. The dissociative will be DXM, which has been shown to not cause vacuolation in the rat brain.
That study was probably conducted with DXM HBr, not DXM polistirex, which is what I'll be taking.
I wonder if taking a potent 5-HT2A receptor antagonist such as mirtazapine in conjunction with an NMDA antagonist could increase the chance of Olney's Lesions, even if said dissociative has been shown to not cause neuronal death? Or do you think the risk will remain the same?
Your thoughts on this matter are humbly requested. Perhaps such discussions will lead to actual research in the future.
I'm sorry in advance if this has all been covered before!
~mec
I've got a question for you guys.
It has become well-known that 5-HT2A receptor agonists prevent NMDA antagonist neurotoxicity in rats:
http://www.nature.com/npp/journal/v18/n1/abs/1395108a.html
I plan to take a dissociative soon. I take 30mgs mirtazapine each night. The dissociative will be DXM, which has been shown to not cause vacuolation in the rat brain.
That study was probably conducted with DXM HBr, not DXM polistirex, which is what I'll be taking.
I wonder if taking a potent 5-HT2A receptor antagonist such as mirtazapine in conjunction with an NMDA antagonist could increase the chance of Olney's Lesions, even if said dissociative has been shown to not cause neuronal death? Or do you think the risk will remain the same?
Your thoughts on this matter are humbly requested. Perhaps such discussions will lead to actual research in the future.
I'm sorry in advance if this has all been covered before!
~mec
